BFM
REVB icon

Boothbay Fund Management’s Revelation Biosciences REVB Stock Holding History

Boothbay Fund Management’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2
Closed -$4.01M – 2138
2021
Q2 		$4.01M Sell
2
-2
-50% -$4.04M 0.13% 172
2021
Q1 		$7.13M Hold
4
– – 0.27% 64
2020
Q4 		$7.11M Buy
+4
New +$8.06M 0.26% 55

Other funds holding REVB

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Boothbay Fund Management's REVB Position: Q3 2021 in Review

Boothbay Fund Management sold out of Revelation Biosciences (REVB) in Q3 2021, closing a stake of 2 shares — an estimated $4.01M sold.

Boothbay Fund Management first reported a position in REVB in Q4 2020 and held it in 3 quarters. The position peaked at $7.13M in Q1 2021. 14 funds tracked by Wall St. Rank hold REVB as of Q3 2021.

  • Boothbay Fund Management reported no remaining Revelation Biosciences position as of Q3 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 2 Revelation Biosciences shares in Q3 2021, an estimated $4.01M.
  • Boothbay Fund Management first reported a position in Revelation Biosciences in Q4 2020 and held it in 3 quarters.
  • Boothbay Fund Management's Revelation Biosciences position peaked at $7.13M in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Revelation Biosciences as of Q3 2021.

Based on Boothbay Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.